Related references
Note: Only part of the references are listed.Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib
Chaowei Ren et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of a PROTAC targeting ALK with in vivo activity
Guoyi Yan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Ning Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
Meng Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Light-induced control of protein destruction by opto-PROTAC
Jing Liu et al.
SCIENCE ADVANCES (2020)
Fundamental aspects of DMPK optimization of targeted protein degraders
Carina Cantrill et al.
DRUG DISCOVERY TODAY (2020)
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective
Andy Pike et al.
DRUG DISCOVERY TODAY (2020)
Systematic Investigation of the Permeability of Androgen Receptor PROTACs
Duncan E. Scott et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
Sebastien L. Degorce et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
Laura Goracci et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
Baishan Jiang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges
Scott D. Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
Xiaotian Kong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Chengwei Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Chelsea E. Powell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Chung Hyo Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeted protein degradation by PROTACs
Taavi K. Neklesa et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
Ho-June Lee et al.
CANCER CELL (2014)
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2013)
Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
Kazutomo Kinoshita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
Hong Ren et al.
CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
Kazutomo Kinoshita et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Avaniyapuram Kannan Murugan et al.
CANCER RESEARCH (2011)
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
Sabina Antonela Antoniu
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors
Kazutomo Kinoshita et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Impact of linker length on the activity of PROTACs
Kedra Cyrus et al.
MOLECULAR BIOSYSTEMS (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One
Timothy W. Corson et al.
ACS CHEMICAL BIOLOGY (2008)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements:: report of 6 cases
RD Gascoyne et al.
BLOOD (2003)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor
CM Coffin et al.
MODERN PATHOLOGY (2001)
Share Paper
